L3VLUP
ProSign in

MDLN · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MDLNJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MDLN
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterMDLNJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 2020none listed holders, n.a.32 holders, $26.6bn
Q1 2021none listed holders, n.a.31 holders, $25.3bn
Q2 2021none listed holders, n.a.37 holders, $25.6bn
Q3 2021none listed holders, n.a.40 holders, $24.1bn
Q4 2021none listed holders, n.a.33 holders, $25.2bn
Q1 2022none listed holders, n.a.35 holders, $28.2bn
Q2 2022none listed holders, n.a.33 holders, $26.9bn
Q3 2022none listed holders, n.a.36 holders, $25.4bn
Q4 2022none listed holders, n.a.35 holders, $27.6bn
Q1 2023none listed holders, n.a.42 holders, $24.5bn
Q2 2023none listed holders, n.a.38 holders, $25.0bn
Q3 2023none listed holders, n.a.37 holders, $18.9bn
Q4 2023none listed holders, n.a.31 holders, $19.0bn
Q1 2024none listed holders, n.a.32 holders, $19.7bn
Q2 2024none listed holders, n.a.35 holders, $20.4bn
Q3 2024none listed holders, n.a.28 holders, $22.3bn
Q4 2024none listed holders, n.a.37 holders, $20.4bn
Q1 2025none listed holders, n.a.32 holders, $20.5bn
Q2 2025none listed holders, n.a.31 holders, $18.4bn
Q3 2025none listed holders, n.a.32 holders, $23.7bn
Q4 202528 holders, $5.5bn29 holders, $27.8bn
Q1 202628 holders, $7.9bn34 holders, $35.6bn
Q2 202621 holders, $9.1bn33 holders, $39.1bn
MDLN

Medline Inc

Holders
21
Reported value
$9.1bn
Buyers
22
Sellers
23

Breadth -1 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
33
Reported value
$39.1bn
Buyers
18
Sellers
21

Breadth -3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MDLN (12)

Artisan Partners LP, Baillie Gifford & Co, Davidson Kempner Capital Management LP, Durable Capital Partners LP, Egerton Capital UK LLP, Element Capital Management LLC, ExodusPoint Capital Management LP, Lone Pine Capital LLC, PDT Partners LLC, Schonfeld Strategic Advisors LLC, Viking Global Investors LP, Winton Group Ltd

Only JNJ (24)

Acadian Asset Management LLC, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Man Group PLC, Markel Group Inc, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →